Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.4% – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price shot up 1.4% on Thursday . The company traded as high as $6.72 and last traded at $6.68. 6,934,035 shares changed hands during trading, a decline of 73% from the average session volume of 25,620,480 shares. The stock had previously closed at $6.58.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Finally, Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a 50 day moving average of $7.68 and a two-hundred day moving average of $7.08. The stock has a market cap of $2.44 billion, a P/E ratio of -4.08 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.42) EPS. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals during the third quarter valued at about $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.